Sangamo Therapeutics Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Sangamo Therapeutics, Inc. -4.09%

Sangamo Therapeutics, Inc.

SGMO

0.25

-4.09%

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) will release earnings for its fourth quarter after the closing bell on Monday, March 30.

Analysts expect the Richmond, California-based company to report quarterly loss of 5 cents per share, versus a loss of 11 cents per share in the year-ago period. The consensus estimate for Sangamo Therapeutics' quarterly revenue is $40.25 million (it reported $7.55 million last year), according to Benzinga Pro.

On March 9, Sangamo Therapeutics announced advancement of the rolling submission of a BLA to the FDA seeking accelerated approval of isaralgagene civaparvovec.

Sangamo Therapeutics shares fell 6.7% to close at $0.3209 on Friday.

Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.

Let's have a look at how Benzinga's most-accurate analysts have rated the company in the recent period.

  • HC Wainwright & Co. analyst Patrick R. Trucchio maintained a Buy rating with a price target of $10 on Feb. 10, 2026. This analyst has an accuracy rate of 47%.
  • Barclays analyst Gena Wang downgraded the stock from Overweight to Equal-Weight and cut the price target from $5 to $1 on Nov. 7, 2025. This analyst has an accuracy rate of 54%.
  • RBC Capital analyst Luca Issi maintained a Sector Perform rating with a price target of $2 on March 18, 2025. This analyst has an accuracy rate of 60%.

Considering buying SGMO stock? Here’s what analysts think:

Photo via Shutterstock

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.